Study protocol for a randomized controlled trial of the NEIVATECH virtual reality system to improve visual function in children with anisometropic amblyopia

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/124222
Información del item - Informació de l'item - Item information
Título: Study protocol for a randomized controlled trial of the NEIVATECH virtual reality system to improve visual function in children with anisometropic amblyopia
Autor/es: Leal-Vega, Luis | Piñero, David P. | Hernández Rodríguez, Carlos Javier | Molina-Martín, Ainhoa | Morales-Quezada, León | Vallelado Álvarez, Ana Isabel | Arenillas, Juan F. | Coco-Martin, María Begoña
Grupo/s de investigación o GITE: Grupo de Óptica y Percepción Visual (GOPV)
Centro, Departamento o Servicio: Universidad de Alicante. Departamento de Óptica, Farmacología y Anatomía
Palabras clave: Anisometropic amblyopia | Neural plasticity | Gamification | Dichoptic training | Perceptual learning | Virtual reality
Área/s de conocimiento: Óptica
Fecha de publicación: 7-jun-2022
Editor: BMC
Cita bibliográfica: BMC Ophthalmology. 2022, 22:253. https://doi.org/10.1186/s12886-022-02466-z
Resumen: Background: Interest in developing alternative methods for the treatment of amblyopia has long been a topic of interest among clinicians and researchers, as prescribed occlusion and penalization therapies do not always provide an effective response and are associated with a high risk of recurrence and non-compliance. Here, we present the protocol of a small-scale RCT to evaluate the safety and clinical efficacy of a novel VR-based system designed to provide binocular vision training to children with anisometropic amblyopia. Methods: We aim to recruit a total of 60 children with anisometropic amblyopia aged 5-17 years with no previous treatment for amblyopia other than refractive correction from the pediatric ophthalmology units of the University Clinical Hospital of Valladolid and the Vithas Medimar International Hospital of Alicante. Children who meet the eligibility criteria and consent to participate will be randomly assigned to a three-month intervention group of 18 half-hour in-office therapy sessions with the NEIVATECH system (group A) or to a parallel group receiving 2 hours of conventional patching per day at home for the same period of time (group B). Assessments of visual function will be carried out before the intervention and at 1, 2 and 3 months, with changes in distance BCVA being the primary outcome measure to be considered. Patient safety, compliance, satisfaction and acceptance to treatment will also be assessed after therapy as other valuable outcome measures. In addition, a rsfMRI scan will be performed on a subgroup of 5 patients from each group at the pre-intervention visit and at the post-intervention visit to test the effects of both therapies on neural plasticity in the visual cortex. Discussion: The NEIVATECH system has been conceived as a serious game designed to provide binocular vision training to anisometropic amblyopic children by complementing the concepts of perceptual learning, dichoptic training and gamification in an immersive VR environment. We hope that this novel approach may lead to greater improvements in vision performance than those provided so far by conventional patching in anisometropic amblyopic children. Trial registration: This protocol was registered with ClinicalTrials.gov (NCT04819386) on 29 March 2021.
Patrocinador/es: This work is funded by the Centre for the Development of Industrial Technology (CDTI) of the Spanish Ministry of Economy, Industry and Competitiveness by means of the 2018 Research Projects program in the context of the “NEIVATECH” project: Neuroplasticity through Virtual Reality for Amblyopia (IDI-20181232). The author DP-P has also been supported by the Spanish Ministry of Economy, Industry and Competitiveness within the Ramón y Cajal program (RYC-2016-20471).
URI: http://hdl.handle.net/10045/124222
ISSN: 1471-2415
DOI: 10.1186/s12886-022-02466-z
Idioma: eng
Tipo: info:eu-repo/semantics/article
Derechos: © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Revisión científica: si
Versión del editor: https://doi.org/10.1186/s12886-022-02466-z
Aparece en las colecciones:INV - GOPV - Artículos de Revistas

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
ThumbnailLeal-Vega_etal_2022_BMCOphthalmol.pdf1,11 MBAdobe PDFAbrir Vista previa


Este ítem está licenciado bajo Licencia Creative Commons Creative Commons